{"organizations": [], "uuid": "6626b511f5b4b15b021ffe98e53217af33366d68", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-first-patient-treated-in-mapi-phar/brief-first-patient-treated-in-mapi-pharmas-phase-ii-clinical-trialof-ga-depot-idUSASB0C2Z4", "country": "US", "domain_rank": 408, "title": "BRIEF-First Patient Treated In Mapi Pharma's Phase II Clinical Trial Of GA Depot", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-30T15:19:00.000+02:00", "replies_count": 0, "uuid": "6626b511f5b4b15b021ffe98e53217af33366d68"}, "author": "", "url": "https://www.reuters.com/article/brief-first-patient-treated-in-mapi-phar/brief-first-patient-treated-in-mapi-pharmas-phase-ii-clinical-trialof-ga-depot-idUSASB0C2Z4", "ord_in_thread": 0, "title": "BRIEF-First Patient Treated In Mapi Pharma's Phase II Clinical Trial Of GA Depot", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-first patient treated in mapi pharma", "sentiment": "negative"}, {"name": "nical trial of ga depot reuters", "sentiment": "none"}, {"name": "reuters) - mapi pharma ltd", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 30, 2018 / 1:19 PM / in 13 minutes BRIEF-First Patient Treated In Mapi Pharma's Phase II Clinical Trial Of GA Depot Reuters Staff 1 Min Read \nJan 30 (Reuters) - Mapi Pharma Ltd: \n* FIRST PATIENT TREATED IN MAPI PHARMAâ€˜S PHASE II CLINICAL TRIAL OF GA DEPOT FOR PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS (PPMS) Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-30T15:19:00.000+02:00", "crawled": "2018-01-30T15:45:05.066+02:00", "highlightTitle": ""}